Combined modality treatment of small cell carcinoma of the bronchus (SCLC) - The EORTC LCCG experience (Englisch)
Nationallizenz
- Neue Suche nach: Gregor, A.
- Neue Suche nach: Postmus, P.
- Neue Suche nach: Burghouts, J.
- Neue Suche nach: Drings, P.
- Neue Suche nach: Morgan, D.
- Neue Suche nach: Cull, A.
- Neue Suche nach: Sahmoud, T.
- Neue Suche nach: Kirkpatrick, A.
- Neue Suche nach: Gregor, A.
- Neue Suche nach: Postmus, P.
- Neue Suche nach: Burghouts, J.
- Neue Suche nach: Drings, P.
- Neue Suche nach: Morgan, D.
- Neue Suche nach: Cull, A.
- Neue Suche nach: Sahmoud, T.
- Neue Suche nach: Kirkpatrick, A.
In:
Lung Cancer
;
11
;
175-176
;
1994
-
ISSN:
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Combined modality treatment of small cell carcinoma of the bronchus (SCLC) - The EORTC LCCG experience
-
Beteiligte:Gregor, A. ( Autor:in ) / Postmus, P. ( Autor:in ) / Burghouts, J. ( Autor:in ) / Drings, P. ( Autor:in ) / Morgan, D. ( Autor:in ) / Cull, A. ( Autor:in ) / Sahmoud, T. ( Autor:in ) / Kirkpatrick, A. ( Autor:in )
-
Erschienen in:Lung Cancer ; 11 ; 175-176
-
Verlag:
-
Erscheinungsdatum:01.01.1994
-
Format / Umfang:2 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Datenquelle:
Inhaltsverzeichnis – Band 11
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
Inhibition of bombesin stimulated mitogenesis in a small-cell lung cancer cell line by demethoxyviridin; a putative inhibitor of receptor-mediated phospholipase D activation| 1994
- 1
-
Epidemiology of smoking and lung cancer: A historical perspective| 1994
- 1
-
Transforming growth factor α (TGFα) is released by a small cell lung cancer (SCLC) cell line and may act as an autocrine growth factor| 1994
- 1
-
Broochoscopic treatment of lung tumorsSutedja, G. / Postmus, P. E. et al. | 1994
- 2
-
Growth-promoting effects of fibroblasts and their fibroblast conditioned medium on lung cancer cells| 1994
- 2
-
Transforming growth factor β (TGFβ) is an autocrine growth factor in two small cell lung cancer cell lines| 1994
- 2
-
The tobacco industry's manipulation of nicotine: Root cause of the modern lung cancer epidemic| 1994
- 2
-
Epidermal growth factor receptor (EGFR) in non small cell lung cancer (NSCLC)| 1994
- 2
-
Protein kinase C isozyme-specific consequences of phorbol ester treatment of lung cancer cell lines| 1994
- 3
-
Constitutive activation of protein kinase C in a human adenocarcinoma of the lung| 1994
- 3
-
Hepatocyte growth factor-scatter factor (HGF/SF)-MET autocrine loop in non-small cell lung carcinoma (NSCLC)| 1994
- 3
-
Effect of hepatocyte growth factor (HGF) on proliferation of human lung cancer cell lines| 1994
- 3
-
Expression of Gα16Q212L in small cell lung cancer (SCLC) cells inhibits in vitro growth| 1994
- 4
-
Protein kinase C alpha abnormalities in human small cell lung carcinoma| 1994
- 4
-
Antitumor activity of an anti-gastrin releasing peptide (GRP) murine monoclonal antibody (2A11). Phase II trial and in vitro correlation with peptide and receptor expression| 1994
- 4
-
Tobacco control worldwide| 1994
- 4
-
Bradykinin analogs: Structural and functional studies in lung cancer cell lines| 1994
- 4
-
Expression of C-jun and CDC2 in human primary lung cancers| 1994
- 5
-
Expression of the GRP autocrine growth system in NCI-H345 SCLC cells requires cell-cell interactions via the H-A-V sequence of the cadherin's first extra-cellular domain| 1994
- 5
-
Detection of bombesin-like peptide receptor s in human lung cancer cell lines with polymerase chain reaction screening| 1994
- 5
-
Expression of receptor tyrosine kinases in lung tumor cell lines| 1994
- 5
-
Immunohistochemical study of epidermal growth factor receptor (EGFr) and the oncoprotein c-erbB2 in lung cancer| 1994
- 6
-
Somatostatin receptor expression in lung cancer| 1994
- 6
-
G proteins coupled to neoplastic cell growth: cloning of human GQ family proteins from small cell lung cancer cells| 1994
- 6
-
Response of non-small cell lung carcinomas to bombesin-like peptides| 1994
- 6
-
G2/M and metaphase/anaphase checkpoints in the cell cycle| 1994
- 7
-
Establishment of anti-idiotype MoAbS to human anti lung cancer MoAb(4G12) for active specific immunotherapy| 1994
- 7
-
The relationships between cell proliferation rate, cell cycle distribution, P185neu production, intrinsic chemoresistance, and the effects of caffeine (CAF) on the chemoresistance in non-small cell lung cancer (NSCLC) cell lines| 1994
- 7
-
Prognostic impact of K-ras genotypes in stage IIIB & IV non-small cell lung cancer (NSCLC), carboplatin (CBDCA) plus etoposide (E) treated patients (PTS)| 1994
- 7
-
A tentative K-ras gene mutation-based genotypic classification of non-small cell lung cancer (NSCLC)| 1994
- 8
-
P53 mutations in human non-small cell lung cancerLai, Bai-Tang et al. | 1994
- 8
-
p53 Mutations and loss of heterozygosity of chromosome 17 in non-small cell lung cancer| 1994
- 8
-
Inactivation of the Rb gene in human cancer| 1994
- 8
-
Effect of wt-P53 gene suppresses the growth of human lung cander cells bearing multiple genetic lesions| 1994
- 8
-
Cyclin D1 overexpression vs. RB inactivation: Alternate mechanisms of growth control evasion in non small cell (NSCLC) and small cell lung cancer (SCLC)?Sclafani, R.A. / Schauer, I. / Siriwardana, S. / Langan, T.A. et al. | 1994
- 9
-
Loss of heterozygosity at chromosome 11P and tumour progression in non-small cell lung cancerFong, K.M. / Zimmerman, P.V. / Smith, P.J. et al. | 1994
- 9
-
Loss of heterozygosity at the MCC/APC loci and prognosis in resected non small cell lung cancerFong, K.M. / Zimmerman, P.V. / Smith, P.J. et al. | 1994
- 9
-
Geographical differences in non-small cell lung cancer K-ras mutationsFong, K.M. / Zimmerman, P.V. / Smith, P.J. et al. | 1994
- 9
-
L-MYC alleles in Australian lung cancer casesFong, K.M. / Zimmerman, P.V. / Smith, P.J. et al. | 1994
- 10
-
Inhibition of proliferation by L-MYC anti-sense DNA for the translational initiation site in human small cell lung cancerDosaka-Akita, H. / Akie, K. / Fujino, M. / Katoh, M. / Kinoshita, I. / Hiroumi, H. / Murakami, A. / Kawakami, Y. et al. | 1994
- 10
-
Effects in the lung and in the blood of rhGM-CSF administration: Differences in cell increase and TNFα release| 1994
- 10
-
Accumulation of p53 protein in primary non-small cell lung cancer (NSCLC) and it's prognostic significance| 1994
- 10
-
Inhibition of proliferation by L-MYC antisense DNA in a small cell lung cancer cell line - analysis of the target sequences| 1994
- 10
-
Control of the G1/S phase transition| 1994
- 11
-
Bombesin receptor regulation of signal transduction pathways and the control of cell growth| 1994
- 11
-
High frequency of P53 mutations in smoking-associated lung cancer, but not in chromate-associated lung cancerKondo, K. / Tsuzuki, H. / Sasa, M. / Sakiyama, S. / Kamamura, Y. / Umemoto, A. / Takahashi, K. / Sumitomo, M. / Uyama, T. / Monden, Y. et al. | 1994
- 11
-
Interphase cytogenetics of primary lung cancer by fluorescence in situ hybridization (fish)| 1994
- 11
-
Regulation by pleural cavity macrophages and peripheral blood monocytes to LAK activity from pleural cavity lymphocytes and peripheral blood lymphocytes in lung cancer patientsTakahashi, Keiji / Sone, Saburo / Uyama, Tadashi / Saito, Seiya / Sumitomo, Masayuki / Ogura, Takeshi / Monden, Yasumasa et al. | 1994
- 11
-
Ras oncogene detection in bronchoalveolar lavage fluid from patients with lung cancer| 1994
- 12
-
The study of histopathological findings and nuclear DNA ploidy pattern of advanced non-small cell lung carcinoma (NSCLC) located peripherally less than 20mm in diameterNagahiro, I. / Aoe, M. / Okabe, K. / Moriyama, S. / Ando, A. / Shimizu, N. et al. | 1994
- 12
-
Have cytokinetic parameters obtained from in vivo labeled lung cancer biopsies prognostic significance?| 1994
- 12
-
Polymorphic sites within APC and MCC loci reveal infrequent loss of heterozygosity in primary human non-small cell lung cancer| 1994
- 12
-
Lymphocyte subsets and natural killer cell percentage in blood and bronchoalveolar lavage in non small cell lung cancer (NSCLC)Elfiky, A. / Shehata, M.Ábo / Salama, O.S. / Khaled, A. / El-Dewairy, S. et al. | 1994
- 13
-
Overexpression of p53 protein correlates with prognosis in non small cell lung cancer (NSCLC)| 1994
- 13
-
Advances in the detection of preneoplasia and early carcinoma: Opening remarks to mini-symposia| 1994
- 13
-
Differences in allelotype between squamous cell carcinomas and adenocarcinomas of the lung| 1994
- 13
-
Mutation and overexpression of p53 gene in patients with primary resected non-small cell lung cancer (NSCLC)| 1994
- 13
-
p53 gene abnormalities in primary lung cancer and metastatic site tumorGemma, Akihiko / Taniguchi, Yasuyuki / Takeda, Yuichiro / Takenaka, Kiyoshi / Shimada, Takashi / Kudoh, Shoji / Niitani, Hisanobu et al. | 1994
- 14
-
Refined mapping of the minimal region of overlap of chromosome 9p deletions associated with malignant mesothelioma and lung cancer| 1994
- 14
-
Different response to IFN- by alveolar macrophages from patients with lung cancer or chronic obstructive pulmonary disease| 1994
- 14
-
p53 and nuclear DNA content in small cell lung cancer (SCLC) are not prognostic for chemosensitivity or survivalAgrenius, V. / Tornling, G. / Auer, G. et al. | 1994
- 14
-
Prognostic implications of peripheral blood lymphocyte subsets in primary lung cancer| 1994
- 15
-
Distribution of p53 mutations in non-small cell lung cancer (NSCLC): Immunohistochemical and molecular analysisEbina, M. / Jones, J.E. / Birrer, M.J. / Mulshine, J.L. / Linnoila, R.I. et al. | 1994
- 15
-
Recurrent cytogenetic alterations in 63 non-small cell lung carcinomas (NSCLC)| 1994
- 15
-
Detection of mutated K-ras sequences in blood from patients with pulmonary carcinomaSorenson, G.D. / Pribish, D.M. / Maurer, L.H. / Valone, F.H. / Memoli, V.A. et al. | 1994
- 15
-
Amplification of a scaffold-attachment-like region on chromosome 9 is a common event in human lung tumors. Detection by arbitrarily primed polymerase chain reaction amplification| 1994
- 16
-
Flow cytometric quantification of PCNA and DNA contents in non-small cell lung cancer| 1994
- 16
-
Molecular changes preceding the onset of invasive lung cancers| 1994
- 16
-
Production and release of neutrophils related cytokine, MIP-1α and IL-8 in human alveolar macrophages stimulated by PSK of biological response modifiers| 1994
- 16
-
DNA ploidy heterogeneity and prognosis of primary lung cancer| 1994
- 16
-
The effects of cytokines on oxygen radical products from pulmonary alveolar cells and peripheral monocytes, and natural killer activity of lymphocytes in lung cancerUejima, H. / Tohda, Y. / Iwanaga, T. / Sugihara, R. / Nakajima, S. et al. | 1994
- 17
-
Mutational analysis of the p53 gene in carcinoma of lung and preneoplastic bronchial epithelium| 1994
- 17
-
A flow cytometric evaluation of peripheral T1N0M0 lung cancer -proposal of new definition of early lung cancer| 1994
- 17
-
A clinical study of p53 protein expression and proliferative activity of primary lung cancer| 1994
- 17
-
P53 protein overexpression in transbronchial biopsy specimens from small cell lung cancer (SCLC) patients| 1994
- 18
-
Frequency and prognostic evaluation of 3P21 deletion in non small cell lung cancers (NSCLC) using microdissection and PCR amplification| 1994
- 18
-
Relationship between the antiproliferative response to interferons, receptor status and presence of interferon genes in NSCLC cell linesHasthorpe, S. / Holland, K.A. / Nink, V. / Lawler, C.B. / Hertzog, P.J. et al. | 1994
- 18
-
Prognostic value of proliferation marker MIB-1 in lung tumors: Quantitative correlation with p53| 1994
- 18
-
Cell proliferation analysis of NSCLC using nuclear cell cycle-associated antibodies| 1994
- 18
-
Immunocytochemistry of neoplastic and preneoplastic respiratory epithelium| 1994
- 19
-
Localization of 9p deletions in lung cancer| 1994
- 19
-
Fine mapping of non-small cell lung cancer loci on chromosome 11p13 and 11p15.5| 1994
- 19
-
K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinomaLi, S. / Rosell, R. / Urban, A. / Font, A. et al. | 1994
- 19
-
Analysis of 3p tumor suppressor loci in human lung cancer| 1994
- 19
-
A rapid new detection method for K-ras point mutations. Point-EXACCT| 1994
- 20
-
Giant cell cancer of the lung (GCCL) and leukocytosis: Search for humoral factors| 1994
- 20
-
Genetic changes in premalignancy| 1994
- 20
-
Genetic elements in the multi-step lung carcinogenesis| 1994
- 20
-
A correlation between mutation of the p53 gene and histological heterogeneity in differentiated adenocarcinomas of the lung, with special reference to metastatic abilityYoshida, Yasuhiro / Inai, Kouki / Kawano, Ryouji / Kisizuchi, Kentarou / Takashi, Nishisaka / Takeshima, Yukio / Yonehara, Shuji et al. | 1994
- 20
-
Proliferative activity and abnormality of p53 gene in metaplasia and dysplasia of bronchial epithelium| 1994
- 21
-
Changes in cell population and tumor necrosis factor, interleukin-6, and interleukin-8 in malignant pleural effusions after treatment with intrapleural tetracycline| 1994
- 21
-
Comparative analysis of tumor suppressor gene loss in lung tumors between uranium miners and smokers| 1994
- 21
-
Genetic changes in premalignancy for cancer detection| 1994
- 21
-
Quanitative evaluation of peripheral blood natural killer cells in surgically treated lung cancer| 1994
- 22
-
Elastolytic activity in primary pulmonary carcinomas (PPC)| 1994
- 22
-
TIMP 1 gene expression in resected lung cancerFong, K.M. / Zimmerman, P.V. / Smith, P.J. et al. | 1994
- 22
-
NSP gene expression as a novel marker of the neuroendocrine phenotype in lung carcinomas| 1994
- 22
-
Evaluation of CK-BB mass concentration in lung cancer| 1994
- 23
-
Cytokines and adhesion molecules in lung cancer| 1994
- 23
-
Modifications of plasma glycosylated residues in lung cancer detected by proton MRS: Effect of tumor extensionKleisbauer, J.P. / Thomas, P. / Vion-Dury, J. / Sciaky, M. / Confort-Gouny, S. / Cozzone, P.J. et al. | 1994
- 23
-
Quality of life endpoints for cancer trials| 1994
- 23
-
Combined use of immunohistochemistry and in situ hybridization for chromogranin A to detect small cell lung cancer with neuroendocrine features| 1994
- 23
-
Expression of mage genes by non-small cell lung carcinomas| 1994
- 24
-
Characterization of the 3′ splicing pattern of parathyroid hormone-related peptide (PTH-rP) and the expression of the PTH-rP gene and the PTH/PTH-rP receptor gene in human lung cancerHidaka, N. / Onouchi, T. / Horiuchi, T. / Hidaka, Y. et al. | 1994
- 24
-
A data-based meta-analysis of randomised trials of chemotherapy versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)Souhami, R.L. / Stewart, L.A. / Arriagada, R. / Parmar, M. / Le Chevalier, T. / Pignon, J.P. et al. | 1994
- 24
-
Establishment and characterization of a human lung adenocarcinoma cell line GLL-1, producing CEA and CA19-9| 1994
- 24
-
Regulation of ICAM-1 expression on lung cancer cells by cytokines: Effects on their adhesion to lak cells and susceptibility to LAK cell cytotoxicity| 1994
- 24
-
Expression of neutral endopeptidase is reduced in lung cancerCohen, Andrea J. / Bunn, Paul A. / Franklin, Wilbur A. / Folkvord, Joy / Miller, York E. et al. | 1994
- 25
-
Gangliosides as antigenic targets for active and passive immunization of patients with small cell lung cancer (SCLC)| 1994
- 25
-
Prognostic significance of the serum protein content in lung cancer (LC)Buccheri, Gianfranco / Ferrigno, Domenico et al. | 1994
- 25
-
NCAM (neural cell adhesion molecule) (CD56) expression by small cell carcinomas (SCC) differs from expression shown by neuroblastoma cell lines as detected by unique monoclonal antibodies KD11 and MG5| 1994
- 25
-
Detection by in situ hybridization of a low expression of nuclear retinoic acid receptor beta (RAR-β) but not RAR-α and RAR-γ in human lung cancer specimens| 1994
- 26
-
Neural cell adhesion molecule (NCAM) expression and clinical features in small cell lung cancer (SCLC), with reference to treatment outcomeSegawa, Y. / Ohnoshi, T. / Hiraki, S. / Ueoka, H. / Tabata, M. / Shibayama, T. / Gemba, K. / Ikubo, S. / Matsuo, K. / Kimura, I. et al. | 1994
- 26
-
Gemcitabine combination therapy for non-small cell lung cancer| 1994
- 26
-
(-) - Epigallocatechin gallate, the main constituent of green tea extract, inhibits lung cancer cell adhesion to endothelial cells| 1994
- 26
-
Steroid receptors in lung cancer cell lines: Expression and regulationKaiser, U. / Hofmann, J. / Gazdar, A.F. / Havemann, K. et al. | 1994
- 26
-
Estrogen and progesterone receptors in the lung cancer tissueYamazaki, S. / Sasamoto, S. / Komatsu, H. et al. | 1994
- 27
-
Prognostic value of biological markers in lung cancer| 1994
- 27
-
Enhancement of adriamycin cytotoxicity by glutathione derivartivesMatsuki, H. / Nakanishi, Y. / Abe, M. / Yatsunami, J. / Kunitake, R. / Kawasaki, M. / Ogino, H. / Hara, N. et al. | 1994
- 27
-
Expression of the MDR1 and MRP multidrug resistance genes by small cell lung cancer cell lines| 1994
- 27
-
Receptors of the steroid hormone superfamily in small cell lung cancer (SCLC) cell linesHavemann, K. / Jaques, G. / Rother, J. / Hoffmann, J. / Kaiser, U. et al. | 1994
- 28
-
Single agent therapy with gemcitabine in lung cancer — A review| 1994
- 28
-
Overexpression of the MRP gene in a multidrug-resistant small cell lung cancer subline| 1994
- 28
-
Immunohistochemical (IHC) study of topoisomerase II (topo II) in patients with non-small cell lung cancer (NBCLC)| 1994
- 28
-
DT-diaphorase as a determinant of sensitivity to mitomycin C and its analogue (KW-2149) in non-small lung cancer cell line under hypoxia| 1994
- 28
-
Cell membranes and cisplatin uptake into a lung cancer cell line and its cisplatin-resistant variant| 1994
- 29
-
Alteration in length of telomeric repeats in lung cancerShirotani, Y. / Hiyama, K. / Ishioka, S. / Inyaku, K. et al. | 1994
- 29
-
Effects of the multidrug resistance modulators dexniguldipine, verapamil, and cyclosporin A on drug accumulation and cytotoxicity in MDR-1 and MRP expressing lung cancer cell lines| 1994
- 29
-
Relationship between tumor response and the nucleotide triphosphates (NTP) to inorganic phosphate (PI) ratio in small cell lung cancerKristjansen, P.E.G. / Kristensen, C.A. / Spang-Thomsen, M. / Quistorff, B. et al. | 1994
- 29
-
MDR1 gene expression and treatment outcome in small cell lung cancer| 1994
- 29
-
In vitro drug sensitivity testing of cell lines from extensive vs limited small cell lung cancer (SCLC) patientsFeigal, E.G. / Steinberg, S.M. / Gazdar, A.F. / Russell, E.K. / Ihde, D.C. / Johnson, B.E. et al. | 1994
- 30
-
Clinical development of irinotecan (CPT-11) in lung cancers| 1994
- 30
-
In vitro evaluation of antimicrotubule agents in human small cell lung cancer (SCLC) cell lines| 1994
- 30
-
High dose etoposide (VP-16) combined with topoisomerase II antagonists. Models for differential protection of normal tissues versus tumor cells| 1994
- 30
-
Establishment and characterization of SN38 (An active metabolite of CPT-11)-resistant human small cell lung cancer (SCLC) cell line| 1994
- 30
-
Induction of P-glycoprotein mediated MultiDrug resistance (Pgp-MDR) is associated with a decrease in ATP/P1, in vivo, whereas induction of altered topoisomerase MDR (at-MDR) is not - an in vivo31P MR spectroscopic study of human SCLC tumor xenografts| 1994
- 31
-
Phase I study of dipydamole as an efflux blocker of doxorubicin in lung and other cancers| 1994
- 31
-
Expression of P53 and MDR1 genes in lung carcinoma: Correlation to clinical chemoresistance| 1994
- 31
-
Resistance to the topoisomerase I active drug topotecan in small cell lung cancer cell lines| 1994
- 31
-
High sensitivity to analogs of ARA-C and topoisomerase I (TOPO I) active drugs in SCLC cells with resistance to TOPO II targeting agents and to alkylating agentsJensen, P.B. / Holm, B. / Sørensen, M. / Sehested, M. / Hansen, H.H. et al. | 1994
- 32
-
Phase II study of topotecan in extensive stage small cell lung cancer| 1994
- 32
-
Resistance modulation and its biochemical mechanisms in acquired cisplatin (CDDP) resistant lung cancer cell line by pentoxifylline (PTX)| 1994
- 32
-
Enhanced recruitment of pyrimidine salvage pathways in N-417 small cell lung cancer cell extracts via 19F NMR and 31P NMR| 1994
- 32
-
Is endocrine hyperactivity a favourable prognostic factor in the chemotherapic treatment of bronchogenic carcinoma?Francini, G. / Clerici, M. / Petrioli, R. / Marsili, S. / Aquino, A. et al. | 1994
- 32
-
Expression of DT-diaphorase in lung cancer cell lines and sensitivity to the novel bioreductive indoloquinone EO9 under oxic and hypoxic conditions| 1994
- 33
-
Identification of type-specific genetic biomarkers for lung cancer using differential mRNA expression fingerprinting| 1994
- 33
-
Interstitial hypertension in lung carcinomas in patients| 1994
- 33
-
Detection of human papillomavirus DNA and E6-E7 mRNA in lung cancer| 1994
- 33
-
Primary normal human bronchial epithelial (NHBE) cells as a model system for CYP1A1 induction in lung carcinogenesis and xeno-biotic metabolism| 1994
- 34
-
Characterization of epithelial cells cultured from human endobronchial explants∗| 1994
- 34
-
The clinical status of topotecan (TPT), a novel inhibitor of topoisomerase| 1994
- 34
-
Treatment of mesothelioma utilizing recombinant adenovirus transfer of the HSVtk gene| 1994
- 34
-
Poor prognosis in non small cell lung cancer (NSCLC) is predicted by components of the plasminogen activation (PA) system| 1994
- 35
-
The role of limited resection in the treatment of early stage lung cancer| 1994
- 35
-
Clinicopathological study of multiple lung cancer cases. A nation-wide autopsy case analysis in Japan from 1958 to 1991| 1994
- 35
-
Novel differentiation of alveolar type II cells during bronchial carcinogenesis favors an oncofetal concept of bronchogenic carcinoma development| 1994
- 36
-
Spectrum of NE expression in lung cancer from aspiration biopsy and autopsy material| 1994
- 36
-
Measurement of cytokeratin 19 fragments as a new lung cancer marker by CYFRA 21-1 enzyme immunoassayTamura, Kenji / Takada, Minoru / Masuda, Noriyuki / Kusunoki, Youko / Matui, Kaoru / Nakagawa, Kazuhiko / Yana, Takashi / Fukuoka, Masahiro et al. | 1994
- 36
-
Distinctive features of primary bronchogenic carcinoma at the lome teaching hospital| 1994
- 36
-
The ratio between pretreatment γ-enolase activity (γ-act) and γ-enolase antigen (γ-ag) concentration in serum of small cell lung cancer (SCLC)-patients: A unique prognostic factor| 1994
- 37
-
Resection for peripheral higher stage lung tumor| 1994
- 37
-
Serum markers CASA, CEA, CYFRA, TPS, and NSE in lung cancer| 1994
- 37
-
Evaluation of clinical usefulness of CAM 123-6, a new tumor marker for pulmonary adenocarcinoma| 1994
- 37
-
Diagnostic value of citology in lung cancer| 1994
- 37
-
CYFRA 21-1: A marker of lung cancerFelletti, R. / Chessa, L. / Cerri, E. / Ropolo, F. / Ratto, G. / Spessa, E / Giorgi, G / Onetto, M. et al. | 1994
- 38
-
Histopathological study of adenocarcinoma and hyperplastic epithelial lesions in the peripheral lung| 1994
- 38
-
Pro-gastrin-releasing peptide is a monitoring tumor marker for evaluation of chemotherapy effects in patients with small cell lung cancer (SCLC)| 1994
- 38
-
Prognostic significance of AgNORs and nuclear area in resected lung adenocarcinomaShiba, M. / Yamaguchi, Y. / Iizasa, T. / Baba, M. / Nomoto, Y. / Kono, H. / Odaka, E. / Otsuji, M. / Tamiya, N. / Iwai, N. et al. | 1994
- 38
-
A clinicopathological study on female squamous cell carcinoma of lungAoe, M. / Nakata, M. / Shimizu, N. / Okabe, K. / Moriyama, S. / Ando, A. et al. | 1994
- 39
-
Immunocytochemistry (ICC) and bone marrow metastases of small cell lung cancer (SCLC)Charloux, A / Fu, L.Y. / Alpert, L / Brisson, M.L. / Small, D / Wolkove, N / Pauli, G / Quoix, E / Kreisman, H et al. | 1994
- 39
-
CYFRA 21-1 as a biological marker of lung cancer. Evaluation of sensitivity, specificity and prognostic roleWieskopf, B. / Demangeat, C. / Purohit, A. / Stenger, R. / Gries, P. / Pauli, G. / Kreisman, H. / Quoix, E. et al. | 1994
- 39
-
CYFRA 21-1 as a new marker in lung cancer| 1994
- 39
-
Tracheal sleeve pneumonectomy for lung cancer. A report of 51 cases| 1994
- 39
-
Histological characteristics of fiberbronchoscopically diagnosed lung cancer in patients, 1973–1992| 1994
- 40
-
Prognostic value of the new tumor marker CYFRA 21-1 in non-small cell lung cancer| 1994
- 40
-
Role of elastotic framework on the tumor development of peripheral lung adenocarcinoma less than 4 cm in diameter| 1994
- 40
-
Evaluation of a new serum tumor marker CYFRA 21.1 for the diagnosis and prognosis of non small cell lung cancer (NSCLL): Preliminary results| 1994
- 40
-
Chronic inhalation of urban ambient air induces multifocal neuroendocrine cell papillomas and hyperplasia in the rat airway epithelium| 1994
- 41
-
Superradical operation for lung cancer-bilateral mediastinal dissection (BMD) with or without cervical dissection (CD)| 1994
- 41
-
The relationship between histological features of tumor and the tumor extent of early squamous cell carcinoma of the bronchus| 1994
- 41
-
Influence of nuclear DNA content on nuclear atypia, chromatin patterns and clinicopathological factors in non-small cell lung cancer| 1994
- 41
-
Immunohistolical findings and postoperative prognosis of Adenocarcinoma| 1994
- 41
-
Analysis of MHC class II antigen expression in cultured lung cancer cells using RNA-PCR method| 1994
- 42
-
Pseudomesotheliomatous carcinomas of the lung: A rare asbestos-associated neoplasm that can be differentiated from epithelial mesothelioma by a combination of histochemistry, immunohistochemistry and electron microscopy| 1994
- 42
-
Analysis of blood group antigen A and flow cytometry in patients with resected stage I and II non-small cell lung cancer (NSCLC)| 1994
- 42
-
Heterogeneity and anaplasia of pleural mesotheliomas: A study of 10 autopsy cases| 1994
- 42
-
Can a blind serum measurement of TPA accurately diagnose a change of disease status, or even anticipate it in lung cancer?Buccheri, Gianfranco / Ferrigno, Domenico et al. | 1994
- 43
-
Clinical evaluation of soluble cytokeratin fragments in sera — a new marker for non small cell lung carcinomaSugama, Y. / Kitamura, S. et al. | 1994
- 43
-
Japanese doctors' preferred treatment choices for their hypothetical non-small cell lung cancer: how they would wish to be treatedMotohiro, A. / Hirota, N. / Komatsu, H. / Yanai, N. et al. | 1994
- 43
-
Second primary lung cancers: An update and international comparison| 1994
- 43
-
Percutaneous fine needle aspiration of chest lesions: Results in 926 patients over 9 years| 1994
- 43
-
Surgical options for patients with mediastinal node involvement| 1994
- 43
-
Clinical implication of pro-gastrin-releasing peptide (proGRP) fragment expression in lung cancer| 1994
- 44
-
Synovial sarcoma-like tumors of lung: A study of 23 cases| 1994
- 44
-
Primary pulmonary rhabdomyosarcoma of the lung in adults: A report of three casesPrzygodzki, R. / Zeren, H. / Finkelstein, S. / Fishback, N. / Moran, C. / Travis, W. / Koss, M. et al. | 1994
- 44
-
Primary fibrosarcoma of lung: Clinicopathologic and immunohistochemical analysis of seven casesZeren, H. / Moran, C. / Fishback, N. / Przygodzki, R. / Travis, W. / Koss, M. et al. | 1994
- 44
-
Primary pulmonary chondrosarcoma: A study of seven cases| 1994
- 45
-
Pro-gastrin-releasing peptide (PROGRP) as a specific tumor marker in patients with small cell lung carcinoma (SCLC)| 1994
- 45
-
Adjuvant radiotherapy on operable (stages I-IIIA) non-small cell lung cancer (NSCLC)| 1994
- 45
-
The use of high resolution cytometry in predicting biological behavior of T1 adenocarcinoma of the lung| 1994
- 45
-
Predicting Progression and Regression of Dysplastic Lesion of the Lung by Quantitative MicroscopyPayne, P.W. / Lam, S. / LeRiche, J.C. / MacAulay, C. / Ikeda, N. / Palcic, B. et al. | 1994
- 45
-
Pleomorphic (giant and spindle cell) carcinoma of lung is genetically distinct from adenocarcinoma| 1994
- 46
-
Tumor-marker CYFRA 21-1 in non small cell lung cancer (NSCLC): Role for detection of recurrence| 1994
- 46
-
Malignancy associated changes (MACs) in bronchial epithelial aspirates and biopsies| 1994
- 46
-
Tumor doubling time, argyrophil nucleolar organizer regions and nuclear DNA content of primary lung cancer and prognostic assessmentUsuda, K. / Nakada, T. / Okaniwa, G. / Saito, Y. / Sagawa, M. / Sato, M. / Kanma, K. / Takahashi, S. / Endo, C. / Chen, Y. et al. | 1994
- 46
-
Tumor markers in patients with advanced lung carcinomaFratta, M. / Cioffi, M. / Rosatt, G. / Chiurazzi, B. / Panza, N. / Pacilio, G. / Sica, V. et al. | 1994
- 47
-
Absence of amplification or rearrangement of the human folate receptor gene in non-small cell lung carcinoma (NSCLC)| 1994
- 47
-
The impact of angiogenesis on the metastasis in resected patients with stage IIIA N2 non small cell lung cancer (NSCLC)Darwish, S. / Fontanini, G. / Minotti, V. / Vignati, S. / Betti, M. / Sidoni, A. / Tonato, M. et al. | 1994
- 47
-
Immunocytological evidence of tumor cells (IETC) spread to the bone marrow and its relationship to prognosis in small cell lung cancer (SCLC)| 1994
- 47
-
Adjuvant therapy for stage I, II and resectable IIIA disease-the North American experience| 1994
- 48
-
CA 125: A useful clinical tumor marker in lung cancer| 1994
- 48
-
Basaloid carcinoma: A histological group with a poor prognosisMoro, D / Brambilla, E / Brichon, P-Y / Brambilla, C et al. | 1994
- 48
-
CYFRA 21-1 a new tumor marker for lung cancer?Lequaglie, C. / Basilico, M. / Giudice, G. / Preda, F. / Ravasi, G. / Maioli, C. / Marino, P. et al. | 1994
- 48
-
The Hu antigen detected by anti-Hu antibody (type I anti-neuronal nuclear antibodies) can be a marker for neuroendocrine tumor| 1994
- 49
-
Clinicopathologic correlation of angiogenesis (CD34, QBend/10) and proliferation (MIB-1) in lung tumors: A quantitative study| 1994
- 49
-
Diagnosis of bronchogenic carcinoma by cytokeratin typing: Correlation with survivalMD Guber, A. / MSc Cohen, R. / MD Siegal, A. / PhD Geiger, B. / MD Bruderman, I. et al. | 1994
- 49
-
Comparison of 2-dimensional polyacrylamide electrophoresis (2-DE) findings between small cell lung cancer and non small cell lung cancerHirano, T. / Iwabuchi, H. / Okuzawa, K. / Franzen, B. / Kawate, N. / Konaka, C. / Ebihara, Y. / Hayata, Y. / Kato, H. / Auer, G. et al. | 1994
- 49
-
Microvessel count (MC) in non small cell lung cancer (NSCLC): Relation to nodal status and late-stage disease| 1994
- 49
-
A meta-analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) using updated individual patient data| 1994
- 50
-
Analysis of clinical characteristics in small cell lung cancer (SCLC) patients with or without positive serum pro-gastrin-releasing peptide (proGRP)| 1994
- 50
-
Carcinosarcoma of lung: An analysis of six casesCheng, Ching-Yuan / Hsu, Shyu-Liang / Huang, Biing-shiun / Huang, Min-Hsiung / Hsu, Wen-Hu / Wang, Liang-Shun / Chien, Kwang-Yu et al. | 1994
- 50
-
Prognostic significance of blood vessel invasion (BVI) by tumour cells in non small cell lung cancer (NSCLC): Preliminary data| 1994
- 51
-
Prognostic factors in lung cancer based on Shanghai population| 1994
- 51
-
Chart in non-small cell carcinoma of the lung| 1994
- 51
-
Subsequent primary cancers among lung cancer patients in FinlandSalminen, E. / Pukkala, E. / Teppo, L. / Pyrhönen, S. et al. | 1994
- 51
-
Comparison of response evaluation in small cell lung cancer, using computerized tomography and chest radiographyDajczman, E. / Hanley, J. / Lisbona, A. / Wolkove, N. et al. | 1994
- 52
-
Management of lung cancer in a general hospital in Spain. Role of a lung cancer committee| 1994
- 52
-
Lacking GSTM1-activity indicates increased lung cancer risk in individuals with asbestos exposure and low tobacco consumption| 1994
- 52
-
Primary report: A new index of molcule epidemiology for woman's lung cancer in China| 1994
- 52
-
Analysis of a type D retroviral capsid gene in a contagious bronchioloalveolar carcinoma of sheep| 1994
- 53
-
A hospital-based lung cancer registry in Flanders / Belgium: Recent data and survival analysis on 2709 patients| 1994
- 53
-
Malignant mesothelioma and duration of asbestos exposure. Correlation with tissue mineral fiber content| 1994
- 53
-
Fractionation in accelerated treatment of lung cancer| 1994
- 53
-
Asbestos program 1987-92| 1994
- 53
-
Lung cancer in patients under 40. Evidence of sex-related differences in histological subtype| 1994
- 54
-
International differences in epidemiology of lung adenocarcinoma (ADC)Charloux, A / Rossignol, M / Purohit, A / Wolkove, N / Small, D / Pauli, G / Quoix, E / Kreisman, H et al. | 1994
- 54
-
Results of the pilot study on radon and lung cancer in the Belgian ArdennesWeynants, P. / Poffijn, A. / Mak, R. / van Laere, K. et al. | 1994
- 54
-
Carcinogens detected in the lung tissues of lung cancer patients - comparison between Fuyuan, China and JapanNakanishi, Y. / Inutsuka, S. / Shigematsu, N. / Hara, N. / Sera, N. / Tokiwa, H. et al. | 1994
- 54
-
Lung cancer in patients under 40. A good prognosis group?| 1994
- 55
-
Factors which contribute to the recent rapid worldwide rise in lung cancer incidence| 1994
- 55
-
The relationship between occupation and human lung cancer deaths in Guangzhou—An analysis| 1994
- 55
-
Urinary nicotine metabolites and lung cancer risk in a female cohort (DOM-Project)Kemmeren, J.M. / de Waard, F. / Ellard, G.A. / van Ginkel, L.A. / Stolker, A.A.M. et al. | 1994
- 55
-
Characterization of apparently normal tissue adjacent to suspicious lesions identified under fluorescence bronchoscopy| 1994
- 56
-
Risk factors for lung cancer in Rio de Janeiro, Brazil: A case-control study| 1994
- 56
-
Lung cancer in Singapore: Late presentation?Hui, K.P. / Chin, N.K. et al. | 1994
- 56
-
Bioassays of benzo(a)pyrene (B(a)P) and lung cancer| 1994
- 56
-
Crocidolite asbestos-mediated DNA strand breakage and 8-hydroxydeoxyguanosine formation are primarily dependent on iron| 1994
- 56
-
Title: 3D radiotherapy: Its potential in treatment of lung cancer| 1994
- 57
-
Clinical features of female lung cancerFujikane, T. / Takahashi, T. / Nishigaki, Y. / Fujita, Y. / Tsuji, T. / Hashizume, K. / Matsumoto, H. / Shimizu, T. / Sakai, E. et al. | 1994
- 57
-
The results of a two year no smoking campaign in a local hospital in JapanMorita, J. / Masuda, E. / Mukai, S. / Kobayashi, H. / Ishikura, H. / Miura, K. / Yoshizawa, K. et al. | 1994
- 57
-
Antismoking program in the school| 1994
- 57
-
Clinicopathological analyses of large cell carcinoma of the lung, especially in relation to coexisting pulmonary diseasesHoriuchi, M. / Tsushimi, M. / Nasu, K. / Kakegawa, T. et al. | 1994
- 58
-
Fractionation and dose issues in non-small cell lung cancer (NSCLC): Revising dose and volume standards, and re-establishing safety and efficacy parameters with three-dimensional (3-D) treatment planning toolsM.D. Turrisi, Andrew T. III et al. | 1994
- 58
-
Alpha activity in lung tissue as a marker of exposure to radon daughters in Mexican population| 1994
- 58
-
Risk of second cancers (SC) in long-term survivors of small cell lung cancer (SCLC)| 1994
- 58
-
Non-small cell lung cancer and PAH-DNA adducts as a biomarkerTang, D.L. / Santella, R.M. / Mayer, J. / Tsai, W-Y. / Perera, F.P. et al. | 1994
- 58
-
Feasibility of use of plasma and urine levels of gastrin releasing peptide and insulin-like growth factor I as potential predictors for risk of second lung cancer development among patients with stage I or II non-small cell lung cancer| 1994
- 59
-
Evaluation of K-ras mutations in sputum samples by single-stranded conformation polymorphism (SSCP)| 1994
- 59
-
Use of urinary cotinine in assessing risk for exposure to environmental tobacco smoke (ETS) in canine lung cancer| 1994
- 59
-
An operated case of bilateral bronchioloalveolar carcinoma, showing familial aggregation of lung cancerM.D. Tsuji, Hiroharu / M.D. Hara, Shinsuke / M.D. Tagawa, Yutaka / M.D. Kawahara, Katsunobu / M.D. Ayabe, Hiroyoshi / M.D. Tomita, Masao et al. | 1994
- 59
-
A report about smoking habits of Italian health personnel| 1994
- 60
-
Antismoking initiatives addressed to Italian armed forces| 1994
- 60
-
Asbestos fibers in anthracotic spots of the parietal pleuraBoutin, C. / Dumortier, P. / Rey, F. / Viallat, J.R. / Leduc, D. / De Vuyst, P. et al. | 1994
- 60
-
Dose-escalation in non-small cell lung cancer using 3-dimensional radiation treatment planning| 1994
- 60
-
Epidemiological review of lung cancer in Vietnam| 1994
- 60
-
Past history in lung cancer patients. Any pathogenetic role?| 1994
- 61
-
Case-control study of the metabolism of all-trans retinoic acid in non-small cell lung cancer| 1994
- 61
-
Establishment of regional sputum screening system to identify dysplastic patients for spore lung cancer trials.∗| 1994
- 61
-
Development of second primary malignacy (SPM) as an obstacle in the treatment of small cell lung cancer (SCLC)| 1994
- 61
-
Changes in lung function and perfusion after irradiation in patients with lung cancerAbratt, R. P. / Willcox, P. A. et al. | 1994
- 61
-
Past history in lung cancer patients. A comparison between two series of patients| 1994
- 62
-
Lung cancer incidence in the Czech Republic in 1970–1990| 1994
- 62
-
Mutagenic effect of cytostatic therapy on chromosomes of patients with lung carcinoma| 1994
- 62
-
Dose esclations for non small cell lung cancers| 1994
- 62
-
Genetic polymorphism of CYP2D6 and lung cancer risk| 1994
- 62
-
Serum Anti-Benzo(a)Pyrene Diolepoxide-DNA antibodies in the general population| 1994
- 63
-
Difference between patients with lung cancer with and witout pleural plaques| 1994
- 63
-
Tonsillectomy and bronchial carcinoma occurence - negative correlationPesut, D. / Radosavljevic-Asic, G. / Marinkovic, D. et al. | 1994
- 63
-
Epidemiology of lung cancer| 1994
- 63
-
The effect of folate and vitamin B12 for treatment of bronchial squamous metaplasia| 1994
- 64
-
Does early respiratory environment influence lung cancer risk?: Evidence from studies in Glasgow and the West of Scotland| 1994
- 64
-
Small Cell Lung Cancer (SCLC) in the left lung treated with chemotherapy and radiotherapy followed, after 5 years, by non-small lung cancer in the other lungM.D. Giura, Raffaele / M.D. Donghi, Marco / M.D. Antonelli, Paola et al. | 1994
- 64
-
Growth factors for small cell lung carcinoma| 1994
- 64
-
Incidence and epidemiology of malignant pleural mesothelioma (MPM) in Chile| 1994
- 64
-
Lung cancer in the Czech Republic: Epidemiological parameters| 1994
- 65
-
Assessment of bone marrow (BM) involvement by magnetic resonance imaging (MRI) in small-cell lung cancer (SCLC)| 1994
- 65
-
Somatostatin analogue scintigraphy in patients with small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC)| 1994
- 66
-
Do prognostic factors change over the course of treatment for patients with small cell lung cancer (SCLC)?| 1994
- 66
-
F8836 chemical chromometry for the diagnosis of lung cancerGuang-Guo, Ren / Dan-jian, Cheng / Tin-Xi, Sheng et al. | 1994
- 66
-
Gene replacement strategies for the prevention and therapy of lung cancer| 1994
- 66
-
Chest x-ray (CXR) screening improves lung cancer (LC) cure rates!| 1994
- 66
-
Acute phase proteins in malignant pleural mesothelioma: Useful markers in differentiating from adenocarcinoma| 1994
- 67
-
The value of lung function measurements for the assessment of chemotherapy of lung cancer patients| 1994
- 67
-
Usefulness of CINE CT-SCAN in diagnosing the lung cancer invading the aorta| 1994
- 67
-
Unusual lung metastasis from cervical and nasopharyngeal cancer: Identification by polymerase chain reaction and in situ hybridization| 1994
- 67
-
Immunoscintigraphy of SCLC xenografts with anti-NCAM MAB 123C3: Improvement of results by internalization| 1994
- 68
-
Neutron imaging of mouse lung adenoma in vivo with JRR-3 TNRF| 1994
- 68
-
Quality of life issues in lung cancer treatment and research| 1994
- 68
-
The clinical evaluation for detecting metastatic lung cancer: A meta-analysisSilvestri, G.A. / Littenberg, B / Colice, G.L. et al. | 1994
- 68
-
Extensive testicular and cutaneous metastases in advanced small cell lung cancer (SCLC). A case report| 1994
- 68
-
Retrospective study of lung-cancer screening films for the improvement of screeningEndo, Katsuyuki / Satou, Yukio / Morikawa, Satoshi et al. | 1994
- 69
-
Trans bronchial echography: A major advance for the assessment of mediastinal involument of lung cancer?| 1994
- 69
-
The dilemma of the contralateral pulmonary nodule| 1994
- 69
-
Analysis of small solitary pulmonary nodules (SPN) by three-dimensional computed tomography based on radiologic-pathologic correlation| 1994
- 69
-
Gadolinium-DTPA enhancement of regeonal lymph nodes of lung cancer in magnetic resonance imagingIwai, N. / Yamaguchi, Y. / Fujisawa, T. / Baba, M. / Shiba, M. / Saito, H. / Kawano, Y. / Tamiya, N. / Nomoto, Y. / Shibuya, K. et al. | 1994
- 70
-
In-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma| 1994
- 70
-
Lung cancer mass screening system with CT images| 1994
- 70
-
Measuring quality of life in patients with lung cancer| 1994
- 70
-
Thoracoscopic staging and diagnosis for lung cancer: University of Maryland experienceKrasna, M.J. / White, C.S. / Aisner, J / Doyle, L.A. / Belani, C.P. et al. | 1994
- 70
-
Results of mass screening for early lung cancer detection, and bronchoscopic approach for re-evaluation of moderate squamous cell atypiaFujita, Y. / Shimizu, T. / Sakai, E. / Hashizume, K. / Takahashi, T. / Nishigaki, Y. / Tsuji, T. / Matsumoto, H. / Fujikane, T. et al. | 1994
- 71
-
Assessment of tumor response to Radiotherapy (RT) or Chemoradiotherapy (CT+RT) using PET 18-F-FDG in lung cancer| 1994
- 71
-
Staging potential of the anti-CEA monoclonal antibody scintigraphy in lung cancerFerrigno, Domenico / Buccheri, Gianfranco / Biggi, Alberto et al. | 1994
- 71
-
Clinical features of superior vena cava syndrome accompanied by primary lung cancer| 1994
- 71
-
Possibility of pulmonary function assessment using computed tomography of the chest| 1994
- 71
-
The lymphatic pathways of non-small cell lung cancer and their implication in curative irradiation treatmentKiricuta, I. C. / Mueller, G. / Stiess, J. / Bohndorf, W. et al. | 1994
- 72
-
Navelbine: The European experience in non small cell lung carcinoma (NSCLC)Chevalier, Thierry Le / Pujol, Jean-Louis / Douillard, Jean-Yves / Alberola, Vicente / Cigolari, Silvio / Brisgand, Denis / Berthaud, Patrice / Martinez, Ana / Depierre, Alain / European investigators et al. | 1994
- 72
-
FDG-PET imaging used to detect bronchogenic carcinoma presenting as a solitary pulmonary nodule or mass| 1994
- 72
-
Clinical TNM staging system in malignant pleural mesotheliomaTammilehto, Lauri / Kivisaari, Leena / Salminen, Ulla-Stina / Maasilta, Paula / Mattson, Karin et al. | 1994
- 72
-
Evaluation of mediastinal and hilar adenopathy with CT and MRI| 1994
- 72
-
Diagnosis of chest wall invasion by lung cancer using turbo flash MR imaging techniqueShiota, T. / Kanaoka, M. / Nakamura, T. / Ono, S. / Matsumura, T. / Yamada, H. / Sato, A. et al. | 1994
- 73
-
Occult lung cancer beyond the brochoscopic visible area: Its rate in cases with sputum cytology positive for lung cancerSato, Masami / Saito, Yasuki / Aikawa, Kouichi / Sakurada, Akira / Yan, Chen / Endo, Chiaki / Usuda, Katuo / Takahashi, Satomi / Kanma, Keiji / Sagawa, Motoyasu et al. | 1994
- 73
-
Thallium-201 single photon emission computed tomography (SPECT) in evaluation of DNA content of primary lung cancer — New technique of preoperative and noninvasive evaluation of DNA ploidy| 1994
- 73
-
A possible role for somatostatin receptor imaging (octreoscan) in small cell lung cancer (SCLC) stagingSoresi, E. / Boffi, R. / Bombardieri, E. / Crippa, F. / Chiti, A. / Colombo, F. / Gramegna, G. / Borghini, U. / Invernizzi, G. et al. | 1994
- 73
-
Tumor doubling time and prognostic assessment of primary lung cancer patientsUsuda, K / Nakada, T / Okaniwa, G / Saito, Y / Sagawa, M / Sato, M / Kanma, K / Takahashi, S / Endo, C / Chen, Y et al. | 1994
- 74
-
Detection of rabbit bronchial cancer with a new photosensitize (HAT-D01) and excimer dye laser fluorescence-image analyzer| 1994
- 74
-
Navelbine® (Vinorelbine) in Non-Small Cell Lung Cancer (NSCLC)| 1994
- 74
-
Chemotherapy response monitoring with FDG positron emission tomography of patients with small cell lung cancer| 1994
- 74
-
Positron emission tomography for improved staging of bronchogenic carcinoma| 1994
- 74
-
Lung cancer with normal chest X-ray. Questions about therapeutic strategy| 1994
- 75
-
Radiographic screening for lung cancer: proposed paradigm for requisite research| 1994
- 75
-
Endobronchial ultrasound-guided needle aspiration. An improved method for diagnosing intrathoracic lymphadenopathy| 1994
- 75
-
The usefulness of serum carcinoembryonic antigen (CEA) for patients (PTS) undergoing diagnostic bronchoscopic examination| 1994
- 75
-
Prognostic models for NSCLC — Prospective and multivariate results| 1994
- 76
-
ECG monitoring during bronchoscopy in patients with carcinoma of the lungsVasic, N. / Mandaric, D. / Radosavljevic, G. / Rebic, P. / Kacar, V. et al. | 1994
- 76
-
Diagnosis of mediastinal metastases in lung cancer: Computerized tomography and cervical mediastinoscopy| 1994
- 76
-
Lung cancer of patients with chronic bronchitis: Diagnostics, early immune changes in blood, treatment| 1994
- 76
-
Intraoperative prognostic factors in non small cell lung cancer (NSCLC)Ratto, G.B. / Tassara, E. / Verna, A. / Fantino, G. / Rovida, S. / Mereu, C. et al. | 1994
- 76
-
Paclitaxel in the treatment of lung cancer| 1994
- 77
-
Neuron specific enolase (NSE), pro-gastrin-releasing peptide (proGRP) and chromogranin A (chromA) are significant prognostic factors in small cell lung cancer (SCLC)| 1994
- 77
-
Lung cancer in patients with human immunodeficiency virus infection| 1994
- 77
-
Radiologic features of lung cancer in HIV-positive patients| 1994
- 77
-
Long-time survival of patients with lung cancer before and after screening| 1994
- 78
-
Comparison of chest x-ray films, computerized tomography of thorax, bronchoscopic results, and operative findings in patients with suspected lung and/or mediastinal lesions| 1994
- 78
-
Imaging of small cell tumours with the radiolabelled somatostatin analogue, III in-pentetreotide| 1994
- 78
-
Docetaxel (Taxotere®): A hemisynthetic taxoid active in lung cancer| 1994
- 78
-
The value of cytogenetic analysis in the diagnosis of malignant pleural effusions| 1994
- 78
-
Total sialic acid, lipid-bound sialic acid, ceruloplasmin, and fibrinogen levels in malign and benign pleural diseasesDr. Numanoǧlu, Numan / Dr. Karayilanoǧlu, Turan / Dr. Gönüllü, Uǧur / Dr. Özdemir, Özlem / Dr. Atakurt, Yildir / Dr. Alper, Doǧanay et al. | 1994
- 79
-
X-ray occult lung cancer detected by sputum cytology. J. Bechtel, W. Kelley, T. Petty, D. Patz, G. Saccomanno. St. Mary's Hospital, Grand Junction, Colorado| 1994
- 80
-
A comparison of treatment outcome in small cell lung cancer (SCLC) in patients younger or older than 70 years| 1994
- 80
-
Lung cancer registry. Actuarial survival in a five year study| 1994
- 80
-
There is a role for chest x-rays for early lung cancer detection: A reappraisal of four randomized controlled trials on lung cancer screening| 1994
- 81
-
Treatment-related deaths in small cell lung cancer (SCLC) trials: Can patients at risk be identified?| 1994
- 81
-
Long term survival in small cell lung cancer — Prognostic factors| 1994
- 81
-
Quality of life (QL) in randomised clinical trials: Are the doctors' assessments as valid as the patients'?| 1994
- 81
-
Induction of interleukin-6 by streptococcal preparation OK-432 in the treatment of carboplatin + etoposide for advanced lung cancer: A preliminary study| 1994
- 82
-
Quality of life (QL) in a randomised controlled trial of dose intensified chemotherapy with or without rHuG-CSF (lenograstim) in small cell lung cancer (SCLC)| 1994
- 82
-
Quality of life (QL) assessment in a multicentre randomised clinical trial of chemotherapy in small cell lung cancer (SCLC)| 1994
- 82
-
Quality of life (QL) assessment in a multicentre randomised clinical trial of two policies of radiotherapy in inoperable non-small cell lung cancer (NSCLC)| 1994
- 82
-
A randomized study of chest x-ray screening for lung cancer as part of the prostate, lung, colorectal, and ovarian (PLCO) trial| 1994
- 82
-
Symptoms at presentation in patients with lung cancer| 1994
- 83
-
Assessment of ‘quality of life’ using a daily diary card in 2 randomised clinical trials (RTC) comparing chemotherapy regimens in small cell lung cancer (SCLC)| 1994
- 83
-
Consenting lung cancer patients to randomized clinical trials| 1994
- 83
-
The influence of patient's personality on the measurement of quality of life before and after chemotherapy. A study using psychological personality test| 1994
- 83
-
A characteristics of pleural effusions in lung cancer patientsTasskova, V. et al. | 1994
- 83
-
Carboplatin plus epirubicin plus VP-16, concurrent 'split course' radiotherapy and adjuvant surgery for limited small cell lung cancerGridelli, C. / D'Aprile, M. / Curcio, C. / Brancaccio, L. et al. | 1994
- 84
-
Risk factors of death due to bone marrow hypoplasia induced by chemotherapy (CT) without use of CSF in 1350 patients with small cell lung cancer (SCLC)| 1994
- 84
-
Long term survival in inoperable non small cell lung (NSCLC): a french database of 100 patients| 1994
- 84
-
Efficacy of CT-MR imaging in lung cancer staging| 1994
- 84
-
Evaluation of cognitive deficits associated with small cell lung cancer| 1994
- 84
-
Long term survivors in small cell lung cancerYosida, T. / Matsui, K. / Masuda, N. / Kusunoki, Y. / Nakagawa, K. / Yana, T. / Fukuoka, M. / Takada, M. et al. | 1994
- 85
-
Cost effectiveness analysis of two chemotherapy regimens in a randomized multicenter trial for stade III and IV non small cell lung cancer| 1994
- 85
-
Informed consent for patients with advanced lung cancer who are eligible to clinical trials in Japan| 1994
- 85
-
Long term survival in small cell lung cancer (SCLC) patients: A French prospective study| 1994
- 85
-
Ketoconazole for the treatment of Cushing's syndrome secondary to ectopic ACTH in patients with primary lung tumors| 1994
- 86
-
Effect of OK-432 in combination with rhG-CSF on thrombocytopenia during chemotherapy for lung cancer| 1994
- 86
-
Anti-CEA monoclonal antibody scintigraphies in lung cancerBuccheri, Gianfranco / Biggi, Alberto / Ferrigno, Domenico et al. | 1994
- 86
-
The investigation of telling the truth to lung cancer patients| 1994
- 86
-
Study on the reasons for the difficulties in being truthful with cancer patients about their diseaseSaito, R. / Tsuchiya, S. / Nakano, H. / Watanabe, S. / Takei, Y. / Makimoto, T. / Nomoto, T. / Ishihara, S. / Takise, A. / Minato, K. et al. | 1994
- 86
-
Lung cancer management; can patients be selected for cost-effective treatment using appropriate prognostic factors?| 1994
- 87
-
Concentration of serum granulocyte colony-stimulating factor (SG-CSF) during chemotherapy-induced granulocytopenia in lung cancer patients assayed by chemiluminescence enzyme immunoassay (CLEIA)| 1994
- 87
-
Clinical effects of high-dose medroxyprogesterone acetate (MPA) in anorexic patients with advanced lung cancer (LC)Buccheri, Gianfranco / Ferrigno, Domenico et al. | 1994
- 87
-
Quality of life (QL) assessments in patients with NSCLC treated on NAVELBINE clinical trials| 1994
- 87
-
Karnofsky and ECOG performance status in lung cancer: Equivalence, construct validity, and predictive validityBuccheri, Gianfranco / Ferrigno, Domenico et al. | 1994
- 88
-
Efficacy of granisetron for the prevention of cisplatin-induced emesis in lung cancer patients| 1994
- 88
-
The alpha-tocopherol, beta-carotene lung cancer prevention study| 1994
- 88
-
Late relapses and non-small cell lung cancers (NSCLC) in 62 patients (PTS) surviving 2 or more years (YRS) free of cancer after treatment for small cell lung cancer (SCLC)| 1994
- 88
-
A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer| 1994
- 88
-
The comparison of quality of life with matching paired method in non-small cell lung cancer chemotherapy-an interim report| 1994
- 89
-
Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument| 1994
- 89
-
Long term survivors in patients with stage IV adenocarcinoma of the lung| 1994
- 89
-
Prognostic factors contributing the long-term relapse-free survival in patients with small cell lung cancer (SCLC) who achieved complete response (CR)| 1994
- 89
-
The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire for use in lung cancer clinical trials| 1994
- 90
-
Phase III randomized double blind placebo controlled trial of cisplatin(P) and etoposide (E) plus megestrol acetate (M)/placebo in extensive stage small cell lung cancer (SCLC)| 1994
- 90
-
An estimate of the cost-effectiveness of combined modality therapy for stage IIIb NSCLC in Canada| 1994
- 90
-
Design and analyses of chemoprevention trials in patients with no evidence of disease(NED)| 1994
- 90
-
Analysis of survival data in 1052 patients with an advanced unresectable non small cell lung cancer: Application of a recursive partitioning and amalgamation algorithm (RECPAM)| 1994
- 90
-
Long term survival after chemotherapy in patients with advanced unresectable non small cell lung cancer (NSCLC): A report by the European lung cancer working party| 1994
- 91
-
Predictability of bone marrow toxicity (BMT) in chemotherapy of small cell lung cancer (SCLC)| 1994
- 91
-
Health related quality of life assessment. The EORTC approach| 1994
- 91
-
Survival in small cell lung cancer. Cancer registry data of Norway| 1994
- 91
-
Audit of management practices and outcome in patients with lung cancer in S.E. of Scotland| 1994
- 92
-
Retinoid chemoprevention of lung cancer| 1994
- 92
-
Analyses of long term survival in small cell lung cancer (SCLC)| 1994
- 92
-
Standard vs palliation chemotherapy in metastatic small cell lung cancer: An analysis on treatment efficacy and quality of life| 1994
- 92
-
The effect of therapy on the quality of survival in small cell lung cancer (SCLC) patients| 1994
- 92
-
Effective symptom relief with moderate dose MVP (mitomycin-C, vinblastine, cisplatin) chemotherapy in advanced non-small cell lung cancer (NSCLC)| 1994
- 93
-
Clinical study on OK-432 with or without G-CSF in CDDP and CQ chemotherapy (CX) for advanced lung cancer| 1994
- 93
-
Phase I and pharmacokinetic study of paclitaxel by a 3-hour intravenous infusion| 1994
- 93
-
Risk of late recurrence and/or second lung cancer after treatment of patients with small cell lung cancer (SCLC)Szczepek, B. / Szymanska, D. / Decker, E. / Wasowska, H. et al. | 1994
- 94
-
Results of the euroscan trial| 1994
- 94
-
Combination chemotherapy and cytokines in the treatment of advanced primary lung cancer: Results of a controlled clinical trialMantovani, G. / Pusceddu, G. / Del Giacco, G.S. et al. | 1994
- 94
-
Effects of a new platinum analog, TRK-710, on human lung cancer cell lines| 1994
- 94
-
Intratumor pharmacokinetics of gemcitabine (dFdC) in ex vivo perfused small cell lung cancer. A new model for pharmacological and metabolic studies in human tumor xenograftsKristjansen, P.E.G. / Roberge, S. / Brown, T.J. / Shipley, L.A. / Jain, R.K. et al. | 1994
- 94
-
Treatment of lung cancer patients with a new biological response modifier obtained from ascites of cancer patients during regression of the tumors| 1994
- 95
-
In vitro interaction between CPT-11 (SN-38) and other anticancer agents in resected lung cancer cells| 1994
- 95
-
Sequential reinfusion of haemopoietic progenitors in whole blood to increase cytotoxic dose intensity in small cell lung cancer (SCLC)| 1994
- 95
-
In Vitro investigation of the combination of two AUC dependent Drugs-Cisplatin and carboplatin| 1994
- 95
-
Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity| 1994
- 96
-
Taxol administered by one-hour infusion: Preliminary results of a phase I/II study comparing two dose schedules| 1994
- 96
-
In vitro and in vivo combined effects of cisplatin and etoposide on small cell lung cancer cell lines| 1994
- 96
-
Phase I and clinical pharmacological evaluation of daily oral etoposide (E) combined with carboplatin (C) in patients with lung cancer| 1994
- 96
-
Cisplatin and teniposide (VM26) chemotherapy for brain metastases in lung cancer. Preliminary results of a phase II trial| 1994
- 96
-
Antioxidants in the chemoprevention of lung cancer| 1994
- 97
-
Treatment characteristics in patients surviving five to 18+ years. An analysis of 1714 consecutive patientsLassen, U. / Østerlind, K. / Hansen, M. / Dombernowsky, P. / Bergman, B. / Hansen, H.H. et al. | 1994
- 97
-
A phase I study of liposome-encapsulated doxorubicin (D-99) and granulocyte colony stimulating factor (G-CSF) in patients with advanced solid tumors| 1994
- 97
-
An experimental study on the local injection of adriamycin-encapsulated liposomes in mediastinal lymph nodes| 1994
- 97
-
Limited sampling models of CPT-11 and SN-38| 1994
- 98
-
Interferon maintenance therapy for small cell lung cancer: Long term survival| 1994
- 98
-
Adenoma-carcinoma sequence in non-mucus producing bronchioloalveolar carcinoma of the lung| 1994
- 98
-
G-CSF and carboplatin-etoposide for treatment of small cell lung cancer| 1994
- 98
-
Teniposide as second-line treatment in relapsed or progressive extensive small cell lung cancer| 1994
- 98
-
Etoposide containing regimen in small cell lung cancer-experience from North India| 1994
- 99
-
A multicentre, randomised, double-blind, placebo controlled, parallel group study to investigate the efficacy and tolerability of leucomax® (molgramostim; rHu GM-CSF) in conjunction with combination chemotherapy in the treatment of intermediate / poor prognosis patients with small cell lung cancer (SCLC)| 1994
- 99
-
Phase I–II study of carboplatin, epirubicin and VP-16 plus G-CSF in extensive small cell lung cancer (SCLC)Gridelli, C. / D'Aprile, M. / Palmeri, S. / Curcio, C. / Gebbia, V. / Veltri, E. / Ianniello, G. / Lo Russo, V. / Gentile, M. / De Placido, S. et al. | 1994
- 99
-
Dose-intensification of vincristine, ifosfamide, carboplatin and etoposide (V-ICE) ±rhGM-CSF in small cell lung cancer| 1994
- 99
-
Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with code chemotherapy and radiotherapy| 1994
- 100
-
Relationship of total dose and dose intensity (DI) to outcome in chemotherapy of small cell lung cancer| 1994
- 100
-
Histologic discriminants of biologic behavior in lung cancer| 1994
- 100
-
Dose intensity (DI) in a randomised trial of weekly versus 3-weekly chemotherapy in small cell lung cancer (SCLC)| 1994
- 100
-
Randomised trial of etoposide cyclophosphamide methotrexate and vincristine versus etoposide and vincristine in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis| 1994
- 100
-
A randomized study comparing vincristine, adriamycin, cyclophosfamide (VAC) to carboplatin, etoposide (CE) in previously untreated small cell lung cancer (SCLC)| 1994
- 101
-
Dose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with G-CSF in small cell lung cancer (SCLC)| 1994
- 101
-
Dose-intensity escalation study of the CDE regimen combined with G-CSF with or without prophylactic ciprofloxacin in small cell lung cancer (SCLC)| 1994
- 101
-
Anticoagulants in small cell lung cancer (SCLC): A randomized clinical trial comparing five weeks of heparin at curative dosage vs five months of low molecular weight heparin at preventive dosage| 1994
- 101
-
A phase II study of cyclophosphamide / adriamycin / vincristine / etoposide (CAVE) alternating with cisplatin / etoposide (PE) in small cell lung cancer (SCLC)Hara, N. / Ichinose, Y. / Kuba, M. / Ichikawa, Y. / Ninomiya, K. / Shima, K. / Yamamoto, H. / Ohta, M. / Ogawa, N. et al. | 1994
- 102
-
Small cell lung cancer (SCLC): A randomized clinical trial of cytoxan, doxorubicin-etoposide (CDE) vs cisplatin-CDE (P-CDE)| 1994
- 102
-
A randomised trial of 4 versus 8 courses of chemotherapy with ifosfamide, epirubicin and etoposide (EVI) in extensive small cell lung cancer (SCLC)| 1994
- 102
-
SWOG 8609 —A phase II trial of teniposide (VM-26) as therapy for extensive small cell lung cancer (SCLC)| 1994
- 102
-
Significance of peripheral airway cell differentiation in lung carcinogenesis| 1994
- 102
-
Cisplatin (DDP) 5 fluorouracil (5FU) induction chemotherapy for cerebral metastases from small cell lung cancer (SCLC)| 1994
- 103
-
A randomised controlled trial of rHuG-CSF (lenograstim) to dose intensify cytotoxic chemotherapy in small cell lung cancer (SCLC)| 1994
- 103
-
Phase II trial of dose intensive chemotherapy with cisplatin, vincristine, doxorubicin and etposide (Tokushima-CODE; T-CODE) against small cell lung cancer (SCLC)| 1994
- 103
-
5-Fluorouracil plus high dose folinic acid for recurrent small cell lung cancer| 1994
- 103
-
Comparison between patients included in or excluded from clinical trials for small cell lung cancer (SCLC)Arpin, D. / Lasset, C. / Chauvin, F. / Cordier, J.F. / Brune, J. / Trillet-Lenoir, V. et al. | 1994
- 104
-
Oral etoposide (VP-16) and IV carboplatin as first line chemotherapy in small cell lung cancer| 1994
- 104
-
Cisplatin + etoposide (CE) versus CE alternated with cyclophosphamide + epirubicin + teniposide (EVE) in small cell lung cancer (SCLC)| 1994
- 104
-
Bcl-2 protein in non-small-cell lung carcinoma. Immunohistochemical evidence of abnormal expression and correlation with survival| 1994
- 104
-
A phase II study of irinotecan combined with cisplatin in patients with small-cell lung cancerKudoh, S. / Kurihara, N. / Fukuoka, M. / Fujiwara, Y. / Furuse, K. / Ikegami, H. / Ariyoshi, Y. et al. | 1994
- 104
-
Final dose intensity (FDI) correlates with chemotherapy outcome in SCLC| 1994
- 105
-
Neglected lung cancerMadjar, S. / Weissberg, D. et al. | 1994
- 105
-
A phase III study of rhGM-CSF in patients receiving aggressive chemotherapy (CT) for small cell lung cancer (SCLC)Alexopoulos, C.G. / Vaslamatzis, M. et al. | 1994
- 105
-
Treatment of small cell lung cancer (SCLC) with taxol (1-hour infusion), carboplatin, and etoposide: Phase II study of an outpatient regimen| 1994
- 105
-
Induction chemotherapy followed by intensification with high-dose (H.D.) chemotherapy in extensive small cell lung cancer (SCLC) — Preliminary results of a phase II trialMeacci, M. / Crinò, L. / De Marinis, F. / Clerici, M. / Contu, A. / Bracarda, S. / Darwish, S. / Noseda, M.A. / Lembo, A. / Rossetti, R. et al. | 1994
- 105
-
Accelerated chemotherapy+GM-CSF in small cell lung cancer (SCLC): A randomized study with or without GM-CSF priming| 1994
- 106
-
Quality versus quantity of life in the treatment of advanced small cell lung cancer (SCLC). A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine| 1994
- 106
-
Radiation injury of the lung| 1994
- 106
-
Early (EAC) versus late (LAC) alternating chemotherapy in small cell lung cancer (SCLC)| 1994
- 106
-
Phase II study on sequential chemotherapy with high-dose epirubicin (HD EPI) and cisplatinum + etoposide (CP+E) in small cell lung cancerCasadio, M. / Martoni, A. / Melotti, B. / Pajetta, V. / Busutti, L. / Pannuti, F. et al. | 1994
- 106
-
Phase II study of Topotecan (TC) in patients (pts) with pretreated small-cell lung cancer (SCLC)Tvede, K. / Ardizzoni, A. / Dombemowsky, P. / Postmus, P. / Buitenhuis, M. / Wanders, J. / van Zandwijk, N. / Krebs, J.B. / Verweij, J. et al. | 1994
- 107
-
Weekly administration of moderate doses of cisplatin (25 mg/m2) and carboplatin (100 mg/m2) as salvage chemotherapy for small cell lung cancer| 1994
- 107
-
Granulocyte colony stimulating factor (G-CSF) enables dose intensification of chemotherapy in small cell lung cancer (SCLC)| 1994
- 107
-
Intensive weekly treatment with alternating non-cross resistant combination chemotherapy and G-CSF support followed by thoracic and prophylactic cranial irradiation for good prognosis patients with small-cell lung cancer (SCLC)Skarlos, D.V. / Samantas, E / Pavlidis, N / Kalaitzidou, E. / Polyzogopoulos, D / Ch, Kalophonos / Loucatou, M / Kardamakis, D / Klouvas, G / Panousaki, E et al. | 1994
- 107
-
Early phase II study of vinorelbine (VNR) in small cell lung cancer| 1994
- 108
-
Daily oral cyclophosphamide for patients with small cell lung cancer (SCLC) unsuitable for standard treatment. A phase I/II study| 1994
- 108
-
Randomised trial comparing weekly with 3 weekly chemotherapy in small cell lung cancer: A cancer research campaign trial| 1994
- 108
-
Two-drugs combination in small cell lung cancer (SCLC): Cispltin (CDDP) and high-dose epirubicin (EPI): Preliminary results| 1994
- 108
-
Cisplatin — Etoposide for small cell lung cancer (SCLC). Six courses is better than four?Veslemes, M. / Polyzos, A. / Latsi, P. / Dimitroulis, J. / Stamatiadis, D. / Orphanidou, D. / Rasidakis, A. / Jordanoglou, J. et al. | 1994
- 108
-
Radiation response in lung cancer and its possible modification| 1994
- 109
-
Carboplatin and etoposide (CE) in newly diagnosed patients with small cell lung cancer (SCLC)| 1994
- 109
-
Teniposide (T) for brain metastases (BN) of small cell lung cancer (SCLC). A phase II study| 1994
- 109
-
Platinum-teniposide alternating with cyclophosphamid-adriamycin in patients with small cell carcinoma (SCC)| 1994
- 110
-
Clinical and pharmacological phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer (NSCLC)| 1994
- 110
-
Phase II study with thymosin α1 (TA1), interferon α2a (IFN), cisplatin (DDP) and etoposide (VP16) in the treatment of advanced non small cell lung cancer (NSCLS)| 1994
- 110
-
Management of chemotherapy in elderly patients with advanced non small cell lung cancer (NSCLC): A phase III randomized trial| 1994
- 110
-
Radiation sensitization of human lung cancer cellsMitchell, James B. / Liebmann, James / Cook, John A. / Sullivan, Francis J. / Ph.D. Wink, David A. et al. | 1994
- 110
-
Phase I study of etoposide in combination with cisplatin and granulocyte colony stimulating factor (G-CSF) in patients with non small cell lung cancer (NSCLC)| 1994
- 111
-
Phase II trial of oral UFT and cisplatin in non-small cell lung cancer| 1994
- 111
-
Transcription of somatostatin receptor subtype 1 and 2 genes in lung cancerThomas, F. / Brambrilla, E. / Friedmann, A. et al. | 1994
- 111
-
A phase II study of low dose vinorelbine in patients with advanced non-small-cell lung cancer (NSCLC)| 1994
- 111
-
A phase II trial of carboplatin (CA) and vindesine (V) in advanced adenocarcinoma of the lungSederholm, C. / Lewensohn, R. / Agrenius, V. / Malmström, A. / Sirzea, F. / Thaning, L. / Ericsson, B. et al. | 1994
- 111
-
Results of a phase II study with vinorelbine (VNB) in patients with advanced non small cell lung cancer (NSCLC)| 1994
- 112
-
A phase-II trial of mitomycin (M), ifosfamide (I) and cisplatin (P) combinaision for non-small cell lung carcinoma (NSCLC)| 1994
- 112
-
Vindesine-ifosfamide-platinum (VIP) chemotherapy in patients with stage III and IV non small cell lung cancer. A phase II trialVansteenkiste, J. / Vandebroek, J. / Marien, S. / Roex, L. / Janssens, G. / Bal, J. / Bertrand, P. / Deman, R. / De Muynck, P. / Ulrichts, H. et al. | 1994
- 112
-
Phase II-trial with 5-day continuous infusion of mitomycin-C in advanced inoperable NSCLCKampf, S. / Neuhauss, R. / Schlüter, I. / Gatzemeier, U. et al. | 1994
- 112
-
Cell kinetics in non-small cell carcinoma of the lung| 1994
- 112
-
A phase-II trial of carboplatin (CBDCA) and 5 fluorouracil (5FU) in advanced non small cell lung cancer (NSCLC)| 1994
- 113
-
Randomized phase II study of vinorelbine (VNR) vs vindesine (VDS) in previously untreated non-small cell lung cancer (NSCLC)| 1994
- 113
-
Mitomycin-ifosfamide-platinum (MIP) vs mip-interferon (MIP-IFN) vs platinum-carboplatin (PC) in the treatment of metastatic non-small cell lung cancer (NSCLC): Results of a fonicap randomized phase II study| 1994
- 113
-
A phase II activity and safety study of oral doxifluridine (5′-dFUR) in elderly patients with advanced non small cell lung cancer (NSCLC)Conte, P.F. / Baldini, E. / Pfanner, E. / Ricci, S. / Falcone, A. / Ceribelli, A. / Sarcina, R. / Comella, G. / Gallo Stampino, C. et al. | 1994